AC-42
AC-42[edit | edit source]
AC-42 is a selective muscarinic acetylcholine receptor agonist that has been studied for its potential therapeutic applications in neurological disorders. It is particularly noted for its selectivity towards the M1 muscarinic receptor subtype, which is implicated in cognitive processes and memory.
Mechanism of Action[edit | edit source]
AC-42 functions by selectively activating the M1 muscarinic receptor, a subtype of the G protein-coupled receptor family. This receptor is predominantly expressed in the central nervous system, including areas such as the hippocampus and cerebral cortex, which are critical for cognitive function. By stimulating these receptors, AC-42 can enhance cholinergic neurotransmission, potentially improving cognitive deficits associated with conditions like Alzheimer's disease.
Pharmacological Properties[edit | edit source]
AC-42 is unique in its ability to selectively target the M1 receptor without significant activity at other muscarinic receptor subtypes, such as M2, M3, M4, and M5. This selectivity reduces the likelihood of side effects commonly associated with non-selective muscarinic agonists, such as bradycardia and gastrointestinal disturbances.
Therapeutic Potential[edit | edit source]
The selective activation of M1 receptors by AC-42 has been explored in preclinical models of cognitive impairment. Studies suggest that AC-42 may improve memory and learning by enhancing synaptic plasticity and long-term potentiation in the hippocampus. These findings have led to interest in AC-42 as a potential treatment for Alzheimer's disease and other forms of dementia.
Research and Development[edit | edit source]
Research on AC-42 is ongoing, with studies focusing on its efficacy, safety, and pharmacokinetics. The compound's ability to cross the blood-brain barrier and its metabolic stability are key factors in its development as a therapeutic agent. Further clinical trials are needed to fully establish its potential benefits and risks in human populations.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
